Skip to content

Effects of Sitagliptin on Gastric Emptying in Healthy Subjects

Effects of Sitagliptin on Gastric Emptying in Healthy Subjects

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00501657
Enrollment
15
Registered
2007-07-16
Start date
2007-07-31
Completion date
2011-12-31
Last updated
2015-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Gastroparesis

Keywords

gastric emptying, glycemia, appetite, incretin hormones

Brief summary

The purpose of this study is to determine the effects of the drug, sitagliptin, on the rate at which the stomach empties, and the release of gut hormones and blood glucose concentrations, after a mashed potato meal in healthy subjects. Sitagliptin has been shown to reduce the blood glucose (sugar) response to a meal and this may potentially be due to slowing of stomach emptying. This is particularly relevant to people who have diabetes, in whom normalization of elevated blood glucose levels is important to maintain health.

Detailed description

The purpose of this study is to evaluate the effect of sitagliptin on gastric emptying, intragastric meal distribution, postprandial glycemia and insulinemia in healthy subjects. Glucagon-like peptide-1 (GLP-1) inhibits gastric emptying, thereby slowing the delivery of nutrients, and their absorption, across the small intestine. The rate of entry of carbohydrate into the small intestine is especially important in patients with diabetes mellitus. Sitagliptin is an orally administered inhibitor of dipeptidyl-peptidase-IV (DPP-IV), the enzyme responsible for the degradation of GLP-1. It is hypothesized that sitagliptin will increase the GLP-1 response to, and thereby slow gastric emptying and diminish the glycemic response to, a carbohydrate-containing meal. Fifteen healthy subjects (male and female) will be studied. Each subject will be studied on two occasions following treatment for 2 days with sitagliptin (100mg once daily) or matching placebo in a randomized, double blind, crossover design. Measurements of gastric emptying, intragastric meal distribution, blood glucose concentrations, gut hormones and appetite will be measured for 4 hours following ingestion of a mashed potato meal.

Interventions

DRUGSitagliptin

100mg mane for 2 days

DRUGPlacebo

100mg mane for 2 days

Sponsors

Merck Sharp & Dohme LLC
CollaboratorINDUSTRY
Royal Adelaide Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Male or female (females must be using an appropriate contraceptive method) * 18 - 45 years * Body mass index (BMI) 19 - 25 kg/m2.

Exclusion criteria

* Subjects with gastrointestinal disease, history of gastrointestinal surgery and/or significant gastrointestinal symptoms * Subjects taking medication known to influence gastrointestinal function * Alcohol intake \> 20 g per day * Smoking \> 10 cigarettes per day * Pregnant and/or lactating females * Calculated creatinine clearance \< 60 ml/min * Exposure to ionising radiation for research purposes in the previous 12 months.

Design outcomes

Primary

MeasureTime frame
Gastric emptying rate4 hours per study

Secondary

MeasureTime frame
Intragastric distribution, gastrointestinal hormone release (GLP-1, GIP), glycemia, insulinemia, appetite4 hours per study

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026